Tizanidne Hydrochloride Capsule
Product Images NDC 71335-2077

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidne Hydrochloride (NDC 71335-2077). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352077)

Label for Tizanidine Hydrochloride 6 mg capsule by Bryant Ranch Prepack. The label shows the product as a blue capsule and includes a comparison to Zanaflex 6 mg capsule by Alkem Laboratories Ltd. It indicates a package size of 30 capsules and storage instructions to keep at room temperature (20°-25°C, 68°-77°F). The label includes a warning about possible drowsiness and displays the NDC 71335-2077 with associated barcodes.*

FDA Label Image

Tiz01 (Tiz01)

Chemical structure of Tizanidine Hydrochloride showing its molecular framework including chlorine, nitrogen, sulfur atoms, and indicated hydrochloride group.*

FDA Label Image

Tiz02 (Tiz02)

Pharmacokinetic line graph showing plasma concentration (ng/mL) of Tizanidine over time (hours) following different dosing regimens. The graph compares 2 x 4 mg tablets and capsules, taken with or without food, plotting concentration changes over 24 hours post-dosing.*

FDA Label Image

Tiz03 (Tiz03)

A line graph depicting improvement in Ashworth Score over time (hours post-dose) for 16 mg tizanidine, 8 mg tizanidine, and placebo groups. The y-axis represents improvement, with values ranging from -5 to 1, and the x-axis shows time from 0 to 6 hours post-dose. The 16 mg dose shows the greatest improvement, followed by 8 mg and then placebo, with error bars indicated for each data point.*

FDA Label Image

Tiz04 (Tiz04)

A line chart comparing improvement in Ashworth Score between tizanidine (mean dose 28.8 mg) and placebo over three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). Tizanidine data points show greater improvement than placebo, with error bars indicating variability.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.